- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4192 - 1,2,3-Triazoles
Patent holdings for IPC class A61K 31/4192
Total number of patents in this class: 1650
10-year publication summary
|
104
|
121
|
117
|
130
|
136
|
130
|
122
|
134
|
107
|
22
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 550 |
29 |
| Achillion Pharmaceuticals, Inc. | 176 |
25 |
| F. Hoffmann-La Roche AG | 7958 |
24 |
| GW Research Limited | 402 |
23 |
| Bristol-myers Squibb Company | 5080 |
22 |
| Idorsia Pharmaceuticals Ltd. | 385 |
19 |
| Merck Sharp & Dohme LLC | 3689 |
19 |
| Novartis AG | 11238 |
18 |
| Merck Patent GmbH | 5909 |
17 |
| Gilead Sciences, Inc. | 1879 |
17 |
| The Regents of the University of California | 18943 |
16 |
| Boehringer Ingelheim International GmbH | 4629 |
16 |
| Board of Regents, The University of Texas System | 5370 |
16 |
| Hoffmann-La Roche Inc. | 3060 |
14 |
| Centre National de La Recherche Scientifique | 9632 |
14 |
| University of Tennessee Research Foundation | 727 |
14 |
| Emory University | 1498 |
13 |
| Merck Sharp & Dohme Corp. | 2247 |
12 |
| AstraZeneca AB | 3042 |
12 |
| Takeda Pharmaceutical Company Limited | 2961 |
12 |
| Other owners | 1298 |